RanjitSBindraMD

PubMed

• Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.
  Minsoo Khang, Ju Hyun Lee, Teresa Lee, Hee-Won Suh, Supum Lee, Alessandra Cavaliere, Amy Rushing, Luiz H Geraldo, Erika Belitzky, Samantha Rossano, Henk M de Feyter, K...> ;Science Translational Medicine. 2023 Nov 1
• Platinum Sensitivity inMutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.
  Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, Daniella Sia, Joseph Paul Eder, Ranjit Bindra, Jane Houldsworth, Patricia LoRusso, Zenta Walther> ;Cancer Investigation. 2023 Sep 1
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
  Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M Stein, Jeremy Kort...> ;Cancer Research Communications. 2023 Jun 1
• Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors.
  Suzanne Xu, Allison Campbell, Veronica Chiang, Ranjit Bindra, Juan Vasquez, Farzana Pashankar> ;Pediatric Blood & Cancer. 2023 Jul 1
• 11 citations
  Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
  Yazhe Wang, Shipra Malik, Hee-Won Suh, Yong Xiao, Yanxiang Deng, Rong Fan, Anita Huttner, Ranjit S Bindra, Vijender Singh, W Mark Saltzman, Raman Bahal> ;Science Advances. 2023 Feb 10
• 1 citations
  Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrentand-mutant Glioma.
  Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pie...> ;Cancer Research Communications. 2023 Feb 1
• 41 citations
  Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
  Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S Barnholtz-Sloan, Brigitta G Baume...> ;Neuro-Oncology. 2023 Jan 5
• 1 citations
  Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brai...
  Jun Jiang, Xun Bao, Yang Yue, David Schiff, Ranjit Bindra, Jing Li> ;Biomedical Chromatography. 2022 Dec 1
• 3 citations
  Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
  Franson, A. (., Franson, A. (., Franson, A. (., Amar Gajjar, Anita Mahajan, Mohamed Abdelbaki, Clarke Anderson, Reuben Antony, Tejus Bale, Ranjit Bindra, Daniel C Bowe...> ;Journal of the National Comprehensive Cancer Network. 2022 Dec 1
• 1 citations
  The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
  Susan E Gueble, Juan C Vasquez, Ranjit S Bindra> ;Current Treatment Options in Oncology. 2022 Nov 1
• 2 citations
  Polymer nanocarriers for targeted local delivery of agents in treating brain tumors.
  Alexander D Josowitz, Ranjit S Bindra, W Mark Saltzman> ;Nanotechnology. 2022 Dec 2
• 2 citations
  Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.
  Charu Singh, Ranjit S Bindra, Peter M Glazer, Juan C Vasquez, Farzana Pashankar> ;Pediatric Blood & Cancer. 2023 Mar 1
• Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
  Sarah Gao, Lan Jin, Jennifer Moliterno, Zachary A Corbin, Ranjit S Bindra, Joseph N Contessa, James B Yu, Park, H. S., Henry S Park> ;Journal of Neurosurgery. 2023 Mar 1
• 25 citations
  Mechanism-based design of agents that selectively target drug-resistant glioma.
  Kingson Lin, Susan E Gueble, Ranjini K Sundaram, Eric D Huseman, Ranjit S Bindra, Seth B Herzon> ;Science. 2022 Jul 29
• 7 citations
  Intrathecal delivery and its applications in leptomeningeal disease.
  Minsoo Khang, Ranjit S Bindra, W Mark Saltzman> ;Advanced Drug Delivery Reviews. 2022 Jul 1
• 7 citations
  In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
  Rana Gbyli, Yuanbin Song, Wei Liu, Yimeng Gao, Giulia Biancon, Namrata S Chandhok, Xiaman Wang, Xiaoying Fu, Amisha Patel, Ranjini Sundaram, Toma Tebaldi, Padmavathi M...> ;Leukemia. 2022 May 1
• 9 citations
  TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
  Ukhyun Jo, Yasuhisa Murai, Keli K Agama, Yilun Sun, Liton Kumar Saha, Xi Yang, Yasuhiro Arakawa, Sophia Gayle, Kelli Jones, Vishwas Paralkar, Ranjini K Sundaram, Jinny...> ;Molecular Cancer Therapeutics. 2022 Jul 5
• 8 citations
  Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
  Sachita Ganesa, Amrita Sule, Ranjini K Sundaram, Ranjit S Bindra> ;Scientific Reports. 2022 Apr 6
• Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy.
  Vikram Jairam, Henry S Park, James B Yu, Ranjit S Bindra, Joseph N Contessa, Krishan R Jethwa> ;Advances in Radiation Oncology. 2022 Mar 21
• 1 citations
  Introduction: Progress Towards Genomically-directed Radiosensitization.
  Gaorav P. Gupta, Ranjit S. Bindra> ;Seminars in Radiation Oncology. 2022 Jan 1
• 1 citations
  Oncometabolites as Regulators of DNA Damage Response and Repair.
  Susan E. Gueble, Ranjit S. Bindra> ;Seminars in Radiation Oncology. 2022 Jan 1
• 4 citations
  Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
  Daiki Ueno, Juan C Vasquez, Amrita Sule, Jiayu Liang, Jinny van Doorn, Ranjini Sundaram, Sam Friedman, Randy Caliliw, Shinji Ohtake, Xun Bao, Jing Li, Huihui Ye, Karla...> ;Oncotarget. 2022 Jan 1
• 1 citations
  Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxic...
  Sophia Gayle, Robert Aiello, Nalin Leelatian, Jason M Beckta, Jane Bechtold, Patricia Bourassa, Johanna Csengery, Robert J Maguire, Dan Marshall, Ranjini K Sundaram, J...> ;NAR Cancer. 2021 Dec 1
• 22 citations
  Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
  Jennifer Garbarino, Jillian Eckroate, Ranjini K. Sundaram, Ryan B. Jensen, Ranjit S. Bindra> ;Translational Oncology. 2021 Jun 9
• 50 citations
  Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
  Yongheng Wang, Yuhang Jiang, Dengshuai Wei, Priya Singh, Yingjie Yu, Teresa Lee, Lingpu Zhang, Hanna K. Mandl, Alexandra S. Piotrowski-Daspit, Xinyuan Chen, Fan Li, Xi...> ;Nature Biomedical Engineering. 2021 May 27
• Join now to see all

Journal Articles

• Krebs-Cycle-Deficient Hereditary Cancer Syndromes Are Defined by Defects in Homologous-Recombination DNA Repair  
  Brian Shuch, Ranjit S Bindra, Christopher D Corso, Peter M Glazer, Nature

Abstracts/Posters

• PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
  Ranjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...
  Ranjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex t... 
  2019 ASCO Annual Meeting - 6/1/2019